Visall

Visali Therapeutics is a biotechnology company focused on developing next-generation therapies for ophthalmic diseases, particularly those affecting the retina. The company's primary focus is on creating long-acting, small molecule inhibitors that target key pathways involved in ocular neovascularization and inflammation. By utilizing innovative drug delivery technologies, Visali aims to reduce the treatment burden for patients with chronic conditions like age-related macular degeneration and diabetic retinopathy. The company is currently advancing its lead programs through pre-clinical development with the goal of providing more durable and effective treatment options than current standards of care.